Levocetirizina Tarbis

Levocetirizine dihydrochloride, the active ingredient in Levocetirizina Tarbis, is a H1 receptor antagonist presented as an oral tablet for oral use. It is employed to relieve symptoms of allergic rhinitis and chronic idiopathic urticaria in adults and adolescents. It provides rapid relief of nasal congestion, sneezing, itching and watery eyes, and reduces the frequency and severity of hives and itching associated with chronic urticaria.

GNH USA supplies Levocetirizina Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and offers reliable logistics for global distribution.

Levocetirizine dihydrochloride is an antihistamine that targets H1‑mediated allergic pathways. - Allergic rhinitis: reduces nasal congestion, sneezing, itching and watery eyes. - Seasonal allergic rhinitis: provides symptom relief during pollen exposure. - Chronic idiopathic urticaria: decreases the number and intensity of hives and associated itching.

Levocetirizine dihydrochloride may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate pain often transient. - Dry mouth: sensation of oral dryness. - Drowsiness: mild sedation, especially at treatment initiation. - Fatigue: feeling of tiredness. - Nausea: occasional stomach upset.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue requiring urgent care. - Anaphylactic reaction: severe allergic response with respiratory distress. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic enzyme elevation: abnormal liver function tests.

Before prescribing levocetirizine, clinicians should consider several precautionary measures. - Renal function assessment: dose may need adjustment in severe renal impairment. - Pregnancy counseling: category B, use only if benefit outweighs risk. - Sedation monitoring: advise patients not to operate machinery if drowsy. - Concomitant CNS depressants: avoid or use with caution due to additive sedation. - Alcohol avoidance: limit intake to reduce drowsiness. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Levocetirizine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels. - Alcohol: enhances sedative effect. - Other antihistamines: additive CNS depression.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., metoprolol): possible altered metabolism. - Theophylline: may increase theophylline plasma concentration. - NSAIDs: risk of enhanced gastrointestinal irritation. - Tricyclic antidepressants: potential increased sedation. - Rifampin: may reduce levocetirizine exposure.